use of taxane-containing induction chemotherapy in combination with concurrent chemoradiotherapy in chinese patients with locally advanced nasopharyngeal carcinoma: a meta-analysis
Clicks: 208
ID: 197967
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
208 views
31 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #103 of 171 articles by views in jurnal tam
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Rui Tian,1,* Hong Xun Ye,2,* Bao Guo Zhang,3 Dong Ying Gu,3 Bing Wen Zhang,1 Zhi Pan Teng,1 Mao Yong Jin,4 Jin Fei Chen,3 Jian Wei Qi1 1Department of E.N.T., Nanjing First Hospital, Nanjing Medical University, Nanjing, 2Department of Oncology, The People’s Hospital of Taixing, Taixing, 3Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 4Department of Technology, Nanjing Delta Biotechnology Co., Ltd., Nanjing, People’s Republic of China *These authors contributed equally to this work Purpose: Taxane-containing induction chemotherapy (IC) regimens in combination with concurrent chemoradiotherapy (CCRT) have been compared with non-taxane-containing IC combined with CCRT in randomized controlled trials (RCTs) in Chinese patients with advanced nasopharyngeal carcinoma (NPC). This meta-analysis aimed to systematically evaluate their clinical efficacy and safety profiling in this ethnic population.Methods: The electronic databases, PubMed, Embase, MEDLINE, and Chinese Biomedical Database, were searched for eligible studies. The outcomes included overall response rate (ORR), 1-year survival rate, and different types of adverse events. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the associations.Results: A total of 12 RCTs (representing 835 patients) were identified. The pooled analysis showed that taxane-containing regimens had a significant improvement in ORR for nasopharyngeal lesion (OR =4.57, 95% CI =1.14–18.30, P=0.032, z=2.15) but not in cervical lymph nodes (OR =1.23, 95% CI =0.65–2.36, P=0.532, z=0.64) and in 1-year survival rates (OR =1.19, 95% CI =0.10–14.82, P=0.893, z=0.13) compared with non-taxane-containing regimens. Regarding the adverse events and toxicities, grade 3–4 leukopenia and neutropenia were significantly different between the two groups (P<0.001) in favor of the non-taxane-containing regimens, but grade 3–4 vomiting was significantly different between the two groups (P<0.005) in favor of the taxane-containing regimens.Conclusion: When combined with CCRT, taxane-containing IC regimens may be more efficient for short-term local control in Chinese patients with locally advanced NPC than the non-taxane-containing IC regimens. Moreover, the major toxic effects, which were bone marrow suppression, could be tolerated by majority of patients. More long-term follow-up and high-quality trials of NPC are needed to validate our findings.Keywords: randomized controlled trials, clinical efficacy, safety, survival rate, adverse events, cervical lymph nodes
| Reference Key |
r2015oncotargetsuse
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Tian R;Ye HX;Zhang BG;Gu DY;Zhang BW;Teng ZP;Jin MY;Chen JF;Qi JW |
| Journal | jurnal tam |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.